SCHEMBL4019199

SCHEMBL4019199

COC(=O)N(C(=O)OC)c1ccccc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.47
HPGD P15428 4/20 0.47
HSD17B10 Q99714 2/20 0.47
HTT P42858 1/20 0.47
ALDH1A1 P00352 5/20 0.46
ALOX15 P16050 1/20 0.46
KMT2A Q03164 2/20 0.45
LMNA P02545 1/20 0.44
HCAR2 Q8TDS4 1/20 0.43
CDC25B P30305 2/20 0.43
APAF1 O14727 1/20 0.42
RECQL P46063 1/20 0.42
CASP6 P55212 1/20 0.42
CACNA1B Q00975 1/20 0.42
APBA1 Q02410 1/20 0.42
MCL1 Q07820 1/20 0.42
CASP8 Q14790 1/20 0.42
TSHR P16473 2/20 0.42
ESR1 P03372 1/20 0.42
ITGB3 P05106 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29952842 0.91 KDM4E (0.44) KDM4EHPGDHSD17B10HTTALDH1A1
SCHEMBL4024575 0.85 KMT2A (0.58) KDM4EHSD17B10ALDH1A1ALOX15KMT2A
SCHEMBL7064355 0.78 ALDH1A1 (0.56) KDM4EHPGDHTTALDH1A1ALOX15
SCHEMBL6387172 0.77 ALDH1A1 (0.50) KDM4EHPGDHSD17B10HTTALDH1A1
SCHEMBL11378935 0.77 KMT2A (0.44) KDM4EHPGDALDH1A1KMT2ALMNA
SCHEMBL6648818 0.77 HTT (0.43) KDM4EHTTALDH1A1ALOX15KMT2A
SCHEMBL138821 0.76 ALDH1A1 (0.48) KDM4EHPGDHSD17B10HTTALDH1A1
SCHEMBL18158039 0.74 ALDH1A1 (0.56) KDM4EHPGDHSD17B10HTTALDH1A1
SCHEMBL972143 0.74 ALDH1A1 (0.56) KDM4EHPGDHSD17B10HTTALDH1A1
SCHEMBL5696331 0.74 L3MBTL1 (0.49) KDM4EHPGDHSD17B10ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1874722-B1 HYDROXAMIC ACID DERIVATIVES AND THE PREPARATION METHOD THEREOF AMOREPACIFIC CORP (KR) 2015-04-08 EP disclosed
US-7485750-B2 Hydroxamic acid derivatives and the preparation method thereof AMOREPACIFIC CORPORATION (KR) 2009-02-03 US disclosed
US-20080242730-A1 Hydroxamic Acid Derivatives and the Preparation Method Thereof AMOREPACIFIC CORPORATION (KR) 2008-10-02 US disclosed
EP-1874722-A1 HYDROXAMIC ACID DERIVATIVES AND THE PREPARATION METHOD THEREOF Amorepacific Corporation (KR) 2008-01-09 EP disclosed
WO-2006118380-A1 HYDROXAMIC ACID DERIVATIVES AND THE PREPARATION METHOD THEREOF AMOREPACIFIC CORPORATION (KR) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242730-A1 Hydroxamic Acid Derivatives and the Preparation Method Thereof COL14A1, CUTA, COL2A1 KDM4E 340/4885HPGD 27/4885HSD17B10 522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.